A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

doi:10.1158/2159-8290.CD-RW2013-203

AACR Publications

Register
Log in
My Cart

Main menu

Home
About
Articles
For Authors
Alerts
News
- Cancer Discovery News
- Journal Press Releases

AACR Publications

User menu

Register
Log in
My Cart

Search

Search for this keyword

Advanced search

Search for this keyword

Advanced Search

Home
About
Articles
For Authors
Alerts
News
- Cancer Discovery News
- Journal Press Releases

Research Watch

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

DOI: 10.1158/2159-8290.CD-RW2013-203 Published October 2013

Article
Info & Metrics

Abstract

Quizartinib has activity and is well tolerated in patients with relapsed or refractory AML.

View Full Text

PreviousNext

October 2013
Volume 3, Issue 10

Table of Contents
Table of Contents (PDF)
About the Cover

Search for this keyword

View this article with LENS

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Message Subject (Your Name) has forwarded a page to you from Cancer Discovery

Message Body (Your Name) thought you would be interested in this article in Cancer Discovery.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discov October 1 2013 (3) (10) OF14; DOI: 10.1158/2159-8290.CD-RW2013-203

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discov October 1 2013 (3) (10) OF14; DOI: 10.1158/2159-8290.CD-RW2013-203

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
- Abstract
Info & Metrics

Cited By...

Research Watch

Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
Pembrolizumab Monotherapy Is Active in Metastatic Prostate Cancer
MYC Superenhancer–Nuclear Pore Binding Increases MYC-Transcript Export

Show more Research Watch

Clinical Trials

Lazertinib Is Safe and Effective in Non–Small Cell Lung Cancer
Pegilodecakin Plus Anti–PD-1 Is Tolerable and Effective
Safety and Preliminary Evidence of Efficacy Shown for Rogaratinib

Show more Clinical Trials

Home
Alerts
Feedback
Privacy Policy

Articles

OnlineFirst
Current Issue
Past Issues

Info For

Authors
Subscribers
Advertisers
Librarians
Reviewers

About Cancer Discovery

About the Journal
Editors
Journal Sections
Permissions
Submit a Manuscript

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Main menu

User menu

Search

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Abstract

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Research Watch

Clinical Trials

Articles

Info For

About Cancer Discovery